-
Something wrong with this record ?
Covalent binding of cisplatin impairs the function of Na(+)/K(+)-ATPase by binding to its cytoplasmic part
M. Huličiak, J. Vacek, M. Sebela, E. Orolinová, J. Znaleziona, M. Havlíková, M. Kubala,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Cisplatin metabolism pharmacology MeSH
- Protein Conformation MeSH
- Models, Molecular MeSH
- Cerebral Cortex enzymology MeSH
- Swine MeSH
- Antineoplastic Agents metabolism pharmacology MeSH
- Sodium-Potassium-Exchanging ATPase antagonists & inhibitors metabolism MeSH
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MeSH
- Protein Binding MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
This study was aimed at verifying the hypothesis that acute kidney failure accompanying cisplatin administration in the cancer therapy could be due to cisplatin interaction with the cytoplasmic part of Na(+)/K(+)-ATPase. Our results demonstrated that cisplatin-binding caused inhibition of Na(+)/K(+)-ATPase, in contrast to other platinated chemotherapeutics such as carboplatin and oxaliplatin, which are known to be much less nephrotoxic. To acquire more detailed structural information, we performed a series of experiments with the isolated large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45 loop) of Na(+)/K(+)-ATPase. Electrochemistry showed that cisplatin is bound to the cysteine residues of the C45 loop, mass spectrometry revealed a modification of the C45 peptide fragment GSHMASLEAVETLGSTSTICSDK, which contains the conserved phosphorylated residue Asp369. Hence, we hypothesize that binding of cisplatin to Cys367 can cause sterical obstruction during the phosphorylation or dephosphorylation step of the Na(+)/K(+)-ATPase catalytic cycle.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12023995
- 003
- CZ-PrNML
- 005
- 20121206114239.0
- 007
- ta
- 008
- 120815e20120227enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2012.02.015 $2 doi
- 035 __
- $a (PubMed)22394404
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Huličiak, Miroslav $u Department of Biophysics, Palacký University in Olomouc, Olomouc, Czech Republic.
- 245 10
- $a Covalent binding of cisplatin impairs the function of Na(+)/K(+)-ATPase by binding to its cytoplasmic part / $c M. Huličiak, J. Vacek, M. Sebela, E. Orolinová, J. Znaleziona, M. Havlíková, M. Kubala,
- 520 9_
- $a This study was aimed at verifying the hypothesis that acute kidney failure accompanying cisplatin administration in the cancer therapy could be due to cisplatin interaction with the cytoplasmic part of Na(+)/K(+)-ATPase. Our results demonstrated that cisplatin-binding caused inhibition of Na(+)/K(+)-ATPase, in contrast to other platinated chemotherapeutics such as carboplatin and oxaliplatin, which are known to be much less nephrotoxic. To acquire more detailed structural information, we performed a series of experiments with the isolated large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45 loop) of Na(+)/K(+)-ATPase. Electrochemistry showed that cisplatin is bound to the cysteine residues of the C45 loop, mass spectrometry revealed a modification of the C45 peptide fragment GSHMASLEAVETLGSTSTICSDK, which contains the conserved phosphorylated residue Asp369. Hence, we hypothesize that binding of cisplatin to Cys367 can cause sterical obstruction during the phosphorylation or dephosphorylation step of the Na(+)/K(+)-ATPase catalytic cycle.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x metabolismus $x farmakologie $7 D000970
- 650 _2
- $a mozková kůra $x enzymologie $7 D002540
- 650 _2
- $a cisplatina $x metabolismus $x farmakologie $7 D002945
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a sodíko-draslíková ATPasa $x antagonisté a inhibitory $x metabolismus $7 D000254
- 650 _2
- $a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032
- 650 _2
- $a prasata $7 D013552
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vacek, Jan
- 700 1_
- $a Sebela, Marek
- 700 1_
- $a Orolinová, Eva
- 700 1_
- $a Znaleziona, Joanna
- 700 1_
- $a Havlíková, Marika
- 700 1_
- $a Kubala, Martin
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 83, č. 11 (20120227), s. 1507-13
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22394404 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20121206114312 $b ABA008
- 999 __
- $a ok $b bmc $g 946143 $s 781323
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 83 $c 11 $d 1507-13 $e 20120227 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20120815/12/02